Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bryce Bass

Physician Assistant Fort Smith, AR Physician Assistant

NPI 1497307664 CMS profile 10695485

7900 Dallas Street, Fort Smith, AR 72903

Open in the dashboard

General payments

$11,314

616 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bryce Bass of Fort Smith, AR is reported in the CMS Open Payments database as having received $11,314 across 616 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,096 127
2024 General $1,837 105
2023 General $2,444 113
2022 General $2,461 138
2021 General $2,477 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bryce Bass
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Bryce Bass were reported at $2,096. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Bryce Bass Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,477 $132 $37–$438 $132
2022 $2,461 $155 $48–$522 $149
2023 $2,444 $167 $52–$557 $160
2024 $1,837 $178 $55–$600 $164
2025 $2,096 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,903 122 payments
  2. Lilly USA, LLC $1,660 79 payments
  3. Novartis Pharmaceuticals Corporation $959 47 payments
  4. Sun Pharmaceutical Industries Inc. $903 46 payments
  5. Regeneron Healthcare Solutions, Inc. $855 43 payments
  6. Genzyme Corporation $759 28 payments
  7. Janssen Biotech, Inc. $490 34 payments
  8. UCB, Inc. $428 30 payments
  9. LEO Pharma Inc. $425 22 payments
  10. Amgen Inc. $326 22 payments
  11. Other $2,606 143 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,852 607 payments
  2. Education $462 9 payments
Products named General payments · program years 2021–2025
  1. TALTZ $1,341 71 payments
  2. DUPIXENT Immunology $1,106 35 payments
  3. SKYRIZI $1,081 75 payments
  4. OLUMIANT $605 31 payments
  5. TREMFYA $567 30 payments
  6. COSENTYX $538 23 payments
  7. RINVOQ $479 17 payments
  8. DUPIXENT Inflammation And Immunology $432 23 payments
  9. ILUMYA $425 25 payments
  10. ADBRY $388 20 payments
  11. Other $6,170 383 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,022

Median for Physician Assistant: 241

Drug cost

$846,244

Median for Physician Assistant: $4,110

Branded share of claims

13.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 16 $353,202
Taltz Autoinjector Ixekizumab Brand 23 $171,276
Dupixent Syringe Dupilumab Brand 36 $142,229
Dupixent Pen Dupilumab Brand 25 $94,054
Otezla Apremilast Brand 15 $68,413
Clobetasol Propionate Generic 95 $4,226
Ketoconazole Generic 210 $3,106
Betamethasone Dipropionate Generic 37 $1,465
Metronidazole Generic 29 $1,176
Fluorouracil Generic 13 $1,147

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$98,890

Of which drugs: $2,309

Medicare patients

685

Average age 74

Services billed

5,104

419 women, 266 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 29%
Ischemic heart disease 28%
Chronic kidney disease 28%
Osteoporosis 22%
Depression 21%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 52 $35

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $139
  • GENZYME CORPORATION $66
$205 61 —
SKYRIZI
  • AbbVie, Inc. $203
$203 16 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $187
$187 — —
Bimzelx
  • UCB, Inc. $147
$147 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $129
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

616 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record